Inventor · disambiguated record
Alexander Marson
Also filed as: MARSON ALEXANDER
13 granted patents·27 pending applications·39 citations·filing 2008–2025
89Inventor score
Files withUNIV CALIFORNIA31WHITEHEAD INST BIOMEDICAL RES5CHEVALIER BRETT1ROTH THEODORE LEE1THE J DAVID GLADSTONE INST A TESTAMENTARY TRUT UNDER THE WILL OF J DAVID GLADSTONE1
Top patents by PatentIndex Score
40 records- 0196US11814624B2Targeted non-viral DNA insertionsUNIV CALIFORNIA·Filed 2021·Granted Nov 14, 2023·6 cites·33 claims
- 0295US11590171B2Targeted replacement of endogenous T cell receptorsUNIV CALIFORNIA·Filed 2022·Granted Feb 28, 2023·2 cites·16 claims
- 0395US11331346B2Targeted replacement of endogenous T cell receptorsUNIV CALIFORNIA·Filed 2021·Granted May 17, 2022·5 cites·18 claims
- 0495US11033584B2Targeted replacement of endogenous T cell receptorsUNIV CALIFORNIA·Filed 2019·Granted Jun 15, 2021·12 cites·31 claims
- 0592US11083753B1Targeted replacement of endogenous T cell receptorsROTH THEODORE LEE·Filed 2021·Granted Aug 10, 2021·8 cites·18 claims
- 0687US12234461B2Targeted non-viral DNA insertionsUNIV CALIFORNIA·Filed 2023·Granted Feb 25, 2025·0 cites·20 claims
- 0786US2025361287A1Targeted replacement of endogenous t cell receptorsUNIV CALIFORNIA·Filed 2025·Application pending·0 cites
- 0883US12398193B2Targeted replacement of endogenous T cell receptorsUNIV CALIFORNIA·Filed 2023·Granted Aug 26, 2025·0 cites·22 claims
- 0983US2023279359A1Wnt pathway stimulation in reprogramming somatic cells with nuclear reprogramming factorsWHITEHEAD INST BIOMEDICAL RES·Filed 2022·Application pending·0 cites
- 1079USRE49281EWnt pathway stimulation in reprogramming somatic cells with nuclear reprogramming factorsWHITEHEAD INST BIOMEDICAL RES·Filed 2019·Granted Nov 8, 2022·1 cites·8 claims
- 1178US9102919B2WNT pathway stimulation in reprogramming somatic cells with nuclear reprogramming factorsCHEVALIER BRETT·Filed 2008·Granted Aug 11, 2015·4 cites·12 claims
- 1275US2025320504A1Targeted non-viral dna insertionsUNIV CALIFORNIA·Filed 2025·Application pending·0 cites
- 1374US2021388362A1Targeted non-viral dna insertionsUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 1473US9593311B2Wnt pathway stimulation in reprogramming somatic cells with nuclear reprogramming factorsWHITEHEAD INST BIOMEDICAL RES·Filed 2015·Granted Mar 14, 2017·1 cites·8 claims
- 1568US2020362355A1Targeted non-viral dna insertionsUNIV CALIFORNIA·Filed 2018·Application pending·0 cites
- 1666US2019284537A1Wnt pathway stimulation in reprogramming somatic cells with nuclear reprogramming factorsWHITEHEAD INST BIOMEDICAL RES·Filed 2019·Application pending·0 cites
- 1764US2025382340A1Dna constructs for improved t cell immunotherapyUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 1861US2025369021A1Genetic engineering of endogenous proteinsUNIV CALIFORNIA·Filed 2025·Application pending·0 cites
- 1960US2017218341A1Wnt pathway stimulation in reprogramming somatic cells with nuclear reprogramming factorsWHITEHEAD INST BIOMEDICAL RES·Filed 2017·Application pending·0 cites
- 2060US2025041338A1Gene targets for t-cell-based immunotherapy to overcome suppressive factorsUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2159US12359179B2Compositions and methods for modifying a target nucleic acidUNIV CALIFORNIA·Filed 2019·Granted Jul 15, 2025·0 cites·16 claims
- 2258US2024115705A1Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277)THE J GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE·Filed 2022·Application pending·0 cites
- 2358US2025025576A1Cell delivery compositions and methods of use thereofUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2457US2024301403A1Method for making car-t librariesUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2556US2025290099A1Materials and methods for targeted genetic manipulations in cellsUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2656US2024392243A1Dna constructs for improved t cell immunotherapy of cancerUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 2753US12473533B2Gene targets for T-cell-based immunotherapyUNIV CALIFORNIA·Filed 2019·Granted Nov 18, 2025·0 cites·10 claims
- 2853US2023226183A1Compositions and methods for altering gamma delta t cell activityUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 2953US2023312673A1Chimeric receptors with diverse co-regulatory sequencesUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 3053US2021207174A1Genetic engineering of endogenous proteinsUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 3152US2021147841A1Compositions and methods for modifying regulatory t cellsUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 3252US2021340496A1Compositions and methods for modifying regulatory t cellsUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 3351US2023212656A1Methods of spatially resolved single cell sequencingUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 3450US11639495B2Methods for selection and generation of genome edited T cellsUNIV CALIFORNIA·Filed 2019·Granted May 2, 2023·0 cites·26 claims
- 3549US2023159957A1Compositions and methods for modifying a target nucleic acidUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 3649US2024398862A1Gene targets for manipulating t cell behaviorUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 3749US2025277786A1Gene activation targets for enhanced human t cell functionTHE J DAVID GLADSTONE INST A TESTAMENTARY TRUT UNDER THE WILL OF J DAVID GLADSTONE·Filed 2022·Application pending·0 cites
- 3848US2023112075A1Compositions and methods for modifying a target nucleic acidUNIV CALIFORNIA·Filed 2021·Application pending·0 cites
- 3947US2023066806A1Pooled knock-in screening and heterologous polypeptides co-expressed under the control of endogenous lociUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 4040US2019388469A1Protein delivery in primary hematopoietic cellsUNIV CALIFORNIA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexander Marson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →